CN103619802B - 脂质模拟物化合物及其用途 - Google Patents

脂质模拟物化合物及其用途 Download PDF

Info

Publication number
CN103619802B
CN103619802B CN201280029374.5A CN201280029374A CN103619802B CN 103619802 B CN103619802 B CN 103619802B CN 201280029374 A CN201280029374 A CN 201280029374A CN 103619802 B CN103619802 B CN 103619802B
Authority
CN
China
Prior art keywords
compound
carrier
agents
drug
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280029374.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103619802A (zh
Inventor
H·格吕尔
S·朗戈埃斯
J·鲁布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Koninklijke Philips NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips NV filed Critical Koninklijke Philips NV
Priority to CN201511036371.6A priority Critical patent/CN108276285A/zh
Publication of CN103619802A publication Critical patent/CN103619802A/zh
Application granted granted Critical
Publication of CN103619802B publication Critical patent/CN103619802B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201280029374.5A 2011-06-16 2012-06-06 脂质模拟物化合物及其用途 Expired - Fee Related CN103619802B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201511036371.6A CN108276285A (zh) 2011-06-16 2012-06-06 新颖脂质模拟物化合物及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11170139A EP2535326A1 (en) 2011-06-16 2011-06-16 Novel lipidomimetic compounds and uses thereof
EP11170139.7 2011-06-16
PCT/IB2012/052829 WO2012172457A1 (en) 2011-06-16 2012-06-06 Novel lipidomimetic compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201511036371.6A Division CN108276285A (zh) 2011-06-16 2012-06-06 新颖脂质模拟物化合物及其用途

Publications (2)

Publication Number Publication Date
CN103619802A CN103619802A (zh) 2014-03-05
CN103619802B true CN103619802B (zh) 2016-01-20

Family

ID=46321195

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280029374.5A Expired - Fee Related CN103619802B (zh) 2011-06-16 2012-06-06 脂质模拟物化合物及其用途
CN201511036371.6A Pending CN108276285A (zh) 2011-06-16 2012-06-06 新颖脂质模拟物化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201511036371.6A Pending CN108276285A (zh) 2011-06-16 2012-06-06 新颖脂质模拟物化合物及其用途

Country Status (7)

Country Link
US (1) US9061062B2 (https=)
EP (2) EP2535326A1 (https=)
JP (1) JP6085296B2 (https=)
CN (2) CN103619802B (https=)
BR (1) BR112013031871A2 (https=)
RU (1) RU2014101173A (https=)
WO (1) WO2012172457A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108276285A (zh) * 2011-06-16 2018-07-13 皇家飞利浦有限公司 新颖脂质模拟物化合物及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037498A2 (en) * 2012-09-07 2014-03-13 Bracco Imaging Spa Paramagnetic solid lipid nanoparticles (pslns) containing metal amphiphilic complexes for mri.
US9663432B2 (en) 2012-12-28 2017-05-30 Dow Corning Toray Co., Ltd. High-purity monoalkenyl-containing glycerin derivative and method of manufacturing same
CN103304445B (zh) * 2013-05-27 2014-10-22 南京大学 阳离子聚甘油酯类脂质及其合成方法和应用
MA47824A (fr) 2017-03-07 2020-01-15 Translate Bio Inc Administration polyanionique d'acides nucléiques
CN115734786A (zh) * 2020-06-15 2023-03-03 博莱科瑞士股份有限公司 超声介导治疗的改进

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1617710A (zh) * 2001-12-12 2005-05-18 阿尔扎公司 递送核酸的脂质体组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JP3017035B2 (ja) * 1993-12-22 2000-03-06 花王株式会社 蛋白質含有食品の改質剤及び改質剤組成物、並びに改質剤で処理した小麦粉製品
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
CN100379404C (zh) * 2003-02-28 2008-04-09 阿尔扎公司 用于减少脂质体诱导的补体激活的脂质体组合物
RU2528104C2 (ru) * 2008-09-10 2014-09-10 Конинклейке Филипс Электроникс Н.В. Носитель лекарственного средства, обеспечивающий контрастное усиление при мрт
EP2535326A1 (en) * 2011-06-16 2012-12-19 Koninklijke Philips Electronics N.V. Novel lipidomimetic compounds and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1617710A (zh) * 2001-12-12 2005-05-18 阿尔扎公司 递送核酸的脂质体组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Lars H. Lindner, et al..Novel temperature-sensitive liposomes with prolonged circulation time.《Clinical Cancer Research》.2004,第10卷2168-2178. *
Novel temperature-sensitive liposomes with prolonged circulation time;Lars H. Lindner, et al.;《Clinical Cancer Research》;20040315;第10卷;2168-2178 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108276285A (zh) * 2011-06-16 2018-07-13 皇家飞利浦有限公司 新颖脂质模拟物化合物及其用途

Also Published As

Publication number Publication date
EP2535326A1 (en) 2012-12-19
JP2014522417A (ja) 2014-09-04
JP6085296B2 (ja) 2017-02-22
EP2720999B1 (en) 2017-08-23
CN108276285A (zh) 2018-07-13
CN103619802A (zh) 2014-03-05
BR112013031871A2 (pt) 2016-12-13
US9061062B2 (en) 2015-06-23
RU2014101173A (ru) 2015-07-27
EP2720999A1 (en) 2014-04-23
WO2012172457A1 (en) 2012-12-20
US20140127135A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
CN102970977B (zh) 用于药物或显像剂的脂质双层载体
CN102149414B (zh) 提供mri对比增强的药物载体
CN102149371B (zh) 螯合两亲聚合物
RU2561035C2 (ru) Восприимчивые к стимулирующему фактору носители для вмч-регулируемой доставки лекарственного средства
CN103619802B (zh) 脂质模拟物化合物及其用途
CN101888857A (zh) 用于图像引导的递送的聚合物药物载体
JP2003530362A (ja) 診断剤をターゲッティングするための脂質ベースの系
EP2067485A1 (en) Drug carrier providing MRI contrast enhancement
JP2014522417A5 (https=)
JP2018197208A (ja) 一酸化窒素内包バブルリポソーム及びその利用
Yadav et al. Advancements in exogeneous techniques for stimuli-sensitive delivery systems
Lokerse et al. Liposomes for hyperthermia triggered drug release
Javadi et al. Letters in Applied NanoBioScience
Javadi et al. Insights into ultrasonic release from eLiposomes
Gruell et al. Chelating amphiphilic polymers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160120

Termination date: 20190606